# Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT03719989** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** azacitidine plus R-GDP

## Key facts

- **NCT ID:** NCT03719989
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719989, "Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03719989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*